Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.

Authors	Elias Jabbour, Matthias Stelljes, Anjali S Advani, Daniel J DeAngelo, Nicola Gökbuget, David I Marks, Wendy Stock, Susan O'Brien, Ryan D Cassaday, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop Kantarjian
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 61 Issue 8 Pg. 2012-2015 (08 2020) ISSN: 1029-2403 [Electronic] United States
PMID	32378440 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References	Inotuzumab Ozogamicin
Topics	Humans Inotuzumab Ozogamicin Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy) Remission Induction Salvage Therapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!